Integra Lifesciences Holdings Corp
IART12.660USD
+0.070+0.56%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
985.39MMarket Cap
LossP/E TTM
More Details of Integra Lifesciences Holdings Corp Company
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Integra Lifesciences Holdings Corp Info
Ticker SymbolIART
Company nameIntegra Lifesciences Holdings Corp
IPO dateAug 16, 1995
CEOPoul (Mojdeh)
Number of employees4396
Security typeOrdinary Share
Fiscal year-endAug 16
Address1100 Campus Road
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone16092750500
Websitehttps://www.integralife.com/
Ticker SymbolIART
IPO dateAug 16, 1995
CEOPoul (Mojdeh)
Company Executives of Integra Lifesciences Holdings Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.59M
-11.20%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%
Mr. Harvinder Singh
Mr. Harvinder Singh
Executive Vice President, President - International Business
Executive Vice President, President - International Business
21.94K
+65.53%
Ms. Mojdeh Poul
Ms. Mojdeh Poul
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Shaundra D. Clay
Ms. Shaundra D. Clay
Independent Director
Independent Director
--
--
Mr. Chris Ward
Mr. Chris Ward
IR Contact Officer
IR Contact Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart M. Essig, Ph.D.
Dr. Stuart M. Essig, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
1.59M
-11.20%
Mr. Christian S. (Chris) Schade
Mr. Christian S. (Chris) Schade
Independent Director
Independent Director
90.03K
+41.78%
Dr. Keith Bradley, Ph.D.
Dr. Keith Bradley, Ph.D.
Independent Director
Independent Director
89.14K
+27.45%
Mr. Michael J. Mcbreen
Mr. Michael J. Mcbreen
Executive Vice President, President - Codman Specialty Surgical
Executive Vice President, President - Codman Specialty Surgical
70.34K
+25.21%
Ms. Lea Daniels Knight
Ms. Lea Daniels Knight
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
58.58K
-4.19%
Mr. Jeffrey Mosebrook
Mr. Jeffrey Mosebrook
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
35.79K
-10.69%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Neurosurgery
208.99M
50.29%
Wound Reconstruction and Care
84.75M
20.39%
Private Label
26.90M
6.47%
By RegionUSD
Name
Revenue
Proportion
United States
306.31M
73.70%
Asia Pacific
47.73M
11.48%
Europe
42.59M
10.25%
Rest of World
18.97M
4.56%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Neurosurgery
208.99M
50.29%
Wound Reconstruction and Care
84.75M
20.39%
Private Label
26.90M
6.47%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.36%
Fuller & Thaler Asset Management Inc.
5.03%
Other
52.94%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.92%
TRU ST Partnership, L.P.
10.93%
Rubric Capital Management LP
9.83%
The Vanguard Group, Inc.
9.36%
Fuller & Thaler Asset Management Inc.
5.03%
Other
52.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
36.53%
Investment Advisor
36.42%
Hedge Fund
18.48%
Corporation
10.93%
Individual Investor
3.20%
Research Firm
2.31%
Pension Fund
1.49%
Bank and Trust
0.44%
Sovereign Wealth Fund
0.04%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
583
73.55M
94.42%
-25.07M
2025Q2
600
89.38M
114.72%
-18.72M
2025Q1
635
87.01M
111.97%
-18.30M
2024Q4
636
81.93M
106.10%
-20.27M
2024Q3
638
82.93M
106.93%
-12.58M
2024Q2
628
84.82M
107.92%
-1.75M
2024Q1
613
79.36M
101.18%
-3.69M
2023Q4
597
79.81M
101.26%
-5.74M
2023Q3
592
81.88M
100.31%
-3.94M
2023Q2
587
82.30M
100.29%
-6.57M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
9.43M
12.11%
-322.52K
-3.31%
Jun 30, 2025
TRU ST Partnership, L.P.
8.52M
10.93%
--
--
Feb 28, 2025
Rubric Capital Management LP
7.35M
9.44%
+2.71M
+58.36%
Jun 30, 2025
The Vanguard Group, Inc.
7.50M
9.63%
+34.14K
+0.46%
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
3.89M
5%
-29.99K
-0.76%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.92M
3.74%
+333.71K
+12.91%
Jun 30, 2025
Invesco Advisers, Inc.
3.18M
4.08%
+51.84K
+1.66%
Jun 30, 2025
State Street Investment Management (US)
2.83M
3.63%
+79.03K
+2.88%
Jun 30, 2025
Boston Management and Research
2.74M
3.52%
--
--
Jun 30, 2025
Paradigm Capital Management, Inc.
2.18M
2.8%
+796.30K
+57.49%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
1.44%
State Street SPDR S&P Health Care Equipment ETF
1.39%
ROBO Global Healthcare Technology & Innovation ETF
1.02%
Invesco S&P SmallCap Health Care ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.43%
Inspire Small/Mid Cap ESG ETF
0.19%
Royce Quant Small-Cap Quality Value ETF
0.13%
Principal U.S. Small-Cap ETF
0.13%
iShares S&P Small-Cap 600 Value ETF
0.12%
State Street SPDR S&P 600 Small Cap Value ETF
0.11%
View more
iShares Neuroscience and Healthcare ETF
Proportion1.44%
State Street SPDR S&P Health Care Equipment ETF
Proportion1.39%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.02%
Invesco S&P SmallCap Health Care ETF
Proportion0.49%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
Inspire Small/Mid Cap ESG ETF
Proportion0.19%
Royce Quant Small-Cap Quality Value ETF
Proportion0.13%
Principal U.S. Small-Cap ETF
Proportion0.13%
iShares S&P Small-Cap 600 Value ETF
Proportion0.12%
State Street SPDR S&P 600 Small Cap Value ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Integra Lifesciences Holdings Corp?
The top five shareholders of Integra Lifesciences Holdings Corp are:
BlackRock Institutional Trust Company, N.A. holds 9.43M shares, accounting for 12.11% of the total shares.
TRU ST Partnership, L.P. holds 8.52M shares, accounting for 10.93% of the total shares.
Rubric Capital Management LP holds 7.35M shares, accounting for 9.44% of the total shares.
The Vanguard Group, Inc. holds 7.50M shares, accounting for 9.63% of the total shares.
Fuller & Thaler Asset Management Inc. holds 3.89M shares, accounting for 5.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.43M shares, accounting for 12.11% of the total shares.
TRU ST Partnership, L.P. holds 8.52M shares, accounting for 10.93% of the total shares.
Rubric Capital Management LP holds 7.35M shares, accounting for 9.44% of the total shares.
The Vanguard Group, Inc. holds 7.50M shares, accounting for 9.63% of the total shares.
Fuller & Thaler Asset Management Inc. holds 3.89M shares, accounting for 5.00% of the total shares.
What are the top three shareholder types of Integra Lifesciences Holdings Corp?
The top three shareholder types of Integra Lifesciences Holdings Corp are:
BlackRock Institutional Trust Company, N.A.
TRU ST Partnership, L.P.
Rubric Capital Management LP
BlackRock Institutional Trust Company, N.A.
TRU ST Partnership, L.P.
Rubric Capital Management LP
How many institutions hold shares of Integra Lifesciences Holdings Corp (IART)?
As of 2025Q3, 583 institutions hold shares of Integra Lifesciences Holdings Corp, with a combined market value of approximately 73.55M, accounting for 94.42% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -20.30%.
What is the biggest source of revenue for Integra Lifesciences Holdings Corp?
In FY2025Q2, the Neurosurgery business generated the highest revenue for Integra Lifesciences Holdings Corp, amounting to 208.99M and accounting for 50.29% of total revenue.
